Beqalzi (sonrotoclax)
BeOne Medicines (ONC)
ApprovedMay 13, 2026
Marketer take
A BCL2 inhibitor for mantle cell lymphoma after a BTK inhibitor, a late-line niche where Jaypirca and CAR-T already compete, so lymphoma-focused hematologist-oncologists are the core audience.
- Sponsor company
- BeOne Medicines (ONC)
- Indication
- To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor
- Therapeutic area
- Oncology, Hematology
- Event
- FDA approval
- Date
- May 13, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?